How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,722 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Advanced-stage Mycosis Fungoides. Role of STAT3, NFKB and NFAT pathways. (PubMed)

Advanced-stage Mycosis Fungoides. Role of STAT3, NFKB and NFAT pathways. The malignant mechanisms that control the development of cutaneous T-cell lymphoma (CTCL) are beginning to be identified. Recent evidence suggests that disturbances in specific intracellular signalling pathways, such as RAS-MAPK, TCR-PLCG1-NFAT and JAK-STAT, may play an essential role in the pathogenesis of CTCL.We collected 100 samples that were submitted for diagnosis of, or a second opinion regarding mycosis fungoides

2019 British Journal of Dermatology

22. Special Considerations in the Treatment of Mycosis Fungoides. (PubMed)

Special Considerations in the Treatment of Mycosis Fungoides. Mycosis fungoides is the most common form of cutaneous T cell lymphoma. Although normally presenting to physicians at an early stage and with an indolent course, mycosis fungoides can have a varied presentation. The National Comprehensive Cancer Network (NCCN) has created guidelines for the treatment and staging of mycosis fungoides. Although comprehensive, in practice these guidelines do not provide specific treatment regimens (...) the possibility of side effects. Additionally, lesions located in the bathing suit distribution are often nonresponsive to first-line therapies for reasons still undetermined. Finally, although well-described, erythroderma secondary to mycosis fungoides is challenging to treat, with controversy surrounding various methods of control. This article both highlights difficult clinical scenarios and reviews the recommended treatment as provided by the NCCN guidelines and provides alternative therapy for lesions

2019 American journal of clinical dermatology

23. Bexarotene as maintenance treatment after other than skin-directed therapy in advanced stage mycosis fungoides: a pilot study. (PubMed)

Bexarotene as maintenance treatment after other than skin-directed therapy in advanced stage mycosis fungoides: a pilot study. Advanced-stage mycosis fungoides (MF) and Sézary Syndrome (SS) patients have a poor quality of life and quickly relapse irrespective of the administered treatment. Most of the available therapies do not warrant long-lasting remission. In the last ten years, the need for an MF maintenance treatment has been investigated in the literature, with most of experiences

2019 Journal of the European Academy of Dermatology and Venereology

24. Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®): Patient Version

Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®): Patient Version Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer (...) Information Summaries [Internet]. Bethesda (MD): ; 2002-. Search term Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) Patient Version PDQ Adult Treatment Editorial Board . Published online: September 7, 2017. This PDQ cancer information summary has current information about the treatment of mycosis fungoides (including Sézary Syndrome). It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health

2017 PDQ - NCI's Comprehensive Cancer Database

25. Chlormethine (Ledaga) - mycosis fungoides-type cutaneous T-cell lymphoma

Chlormethine (Ledaga) - mycosis fungoides-type cutaneous T-cell lymphoma 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/CHMP/13156/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report (...) purified HPRT hypoxanthine-guanine phosphoribosyltransferase IARC International Agency for Research on Cancer IC50 half-maximal inhibitory concentration ICH International Conference on Harmonisation IID Inactive Ingredient Database i.p. intraperitoneal i.v. intravenous IR InfraredKF Karl Fischer titration LD50 median lethal dose MDA malondialdehyde MDEA N-methyldiethanolamine MF mycosis fungoides MF-type CTC mycosis fungoides-type cutaneous T-cell lymphoma MNNG N-methyl-N´-nitro-N-nitrosoguanidine MTD

2017 European Medicines Agency - EPARs

26. Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. (PubMed)

Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. •Active cancers and inflammation increase the risk for venous thromboembolism. It is unknown whether this applies to mycosis fungoides and parapsoriasis.•Patients with mycosis fungoides and parapsoriasis have increased risk for venous thromboembolism.•These findings should increase awareness of comorbidities as part of the disease spectrum in patients (...) with mycosis fungoides and parapsoriasis.Copyright © 2018. Published by Elsevier Inc.

2018 Journal of American Academy of Dermatology

27. CD8-positive lymphomatoid papulosis (type D): Some lesions may lack CD30 expression and overlap histologically with mycosis fungoides. (PubMed)

CD8-positive lymphomatoid papulosis (type D): Some lesions may lack CD30 expression and overlap histologically with mycosis fungoides. CD8+ lymphomatoid papulosis is frequently indistinguishable histopathologically from primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma except for the expression of CD30. However, absent or weak expression of CD30 has been rarely reported in cases of CD8+ LyP.We aim to study the clinical and pathologic features of cases of CD8+ LyP (...) with CD30 expression and therefore resembled mycosis fungoides and type B LyP. CD5 and CD7 were frequently lost regardless of the CD30 status. Expression of cytotoxic markers was not different between the two groups. In the two cases with lack of CD30 expression, subsequent biopsies showed classic features of CD8+ LyP with strong expression of CD30.CD8+ LyP with lack of expression of CD30 may have distinct histopathologic features that resemble mycosis fungoides and LyP type B. Clinically

2018 International Journal of Dermatology

28. Erratum: Folliculotropic Mycosis Fungoides in 20 Korean Cases: Clinical and Histopathologic Features and Response to Ultraviolet A-1 and/or Photodynamic Therapy (PubMed)

Erratum: Folliculotropic Mycosis Fungoides in 20 Korean Cases: Clinical and Histopathologic Features and Response to Ultraviolet A-1 and/or Photodynamic Therapy [This corrects the article on p. 192 in vol. 30, PMID: 29606817.].

Full Text available with Trip Pro

2018 Annals of dermatology

29. Leser-Trélat Sign Presenting in a Patient with Relapsing Mycosis Fungoides (PubMed)

Leser-Trélat Sign Presenting in a Patient with Relapsing Mycosis Fungoides The Leser-Trélat sign is a rare sign of some malignant tumors and is characterized by the sudden appearance of seborrheic keratosis in association with an underlying malignancy. We describe a 60-year-old Saudi man with mycosis fungoides (MF) who developed numerous, rapidly growing, seborrheic keratoses on his face and back. To the best of our knowledge, this is the first reported case of MF with the Leser-Trélat sign

Full Text available with Trip Pro

2018 Case reports in oncology

30. Clinical outcomes and prognostic factors in patients with mycosis fungoides who underwent radiation therapy in a single institution (PubMed)

Clinical outcomes and prognostic factors in patients with mycosis fungoides who underwent radiation therapy in a single institution We aimed to evaluate clinical outcomes including progression-free survival (PFS), overall survival (OS), partial response, and complete response in patients who underwent radiation therapy (RT) for mycosis fungoides (MF). Also, we sought to find prognostic factors for clinical outcomes. Materials and.Total 19 patients confirmed with MF between 1999-2015 were

Full Text available with Trip Pro

2018 Radiation oncology journal

31. Palliative Radiotherapy for Disfiguring Mycosis Fungoides Lesion: A Key Treatment to Reduce Psychological and Social Impact (PubMed)

Palliative Radiotherapy for Disfiguring Mycosis Fungoides Lesion: A Key Treatment to Reduce Psychological and Social Impact Mycosis Fungoides (MF) is a rare disease with a relatively good prognosis at early stage. However, skin lesions can impair quality of life due to extensive skin lesions. In some cases, skin lesions, and especially those of the face, become visible and change the physical appearance of the patients. This aspect can deeply affect patients psychologically and can impact

Full Text available with Trip Pro

2018 Case reports in dermatological medicine

32. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. (PubMed)

Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Our current mycosis fungoides (MF) and Sézary Syndrome (SS) staging system includes blood-classification from B0-B2 for patch/plaque/tumour or erythroderma based on manual Sézary counts but results from our EORTC survey confirm these are rarely performed in patch/plaque/tumour MF, and there is a trend towards using flow

Full Text available with Trip Pro

2018 European Journal of Cancer

33. The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. (PubMed)

The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. This pathology PILOT study aims to define the role and feasibility of centralized pathology review in a cohort of 75 patients from different centers in the United States and Europe using digital slide scanning. The pathologic material from 75 patients who had been diagnosed with mycosis fungoides/Sézary syndrome

2018 American Journal of Surgical Pathology

34. Mogamulizumab-induced phosensitivity in patients with mycosis fungoides and other T cell neoplasms. (PubMed)

Mogamulizumab-induced phosensitivity in patients with mycosis fungoides and other T cell neoplasms. Mogamulizumab (Mog) is a defucosylated, therapeutic monoclonal antibody, targeting CCR4 and was first approved in Japan for the treatment of adult T-cell leukaemia/lymphoma (ATLL), followed by cutaneous T-cell lymphoma and peripheral T-cell lymphoma.To retrospectively investigate development of photosensitivity in patients with mycosis fungoides and other T-cell neoplasms after treatment (...) with Mog.We treated seven cutaneous lymphoma patients with Mog. Upon combination treatment with narrow-band UVB, we noticed that four patients developed photosensitivity dermatitis following Mog therapy, including two cases of mycosis fungoides, one case of adult T-cell leukaemia/lymphoma and one case of EB virus-associated T-cell lymphoproliferative disorder. Phototest was performed with UVA and UVB, and immunohistochemical staining for CD4, CD8 and Foxp3 was conducted in both photosensitivity

2018 Journal of the European Academy of Dermatology and Venereology

35. Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides

Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pembrolizumab (...) in Treating Patients With Stage IB-IV Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03695471 Recruitment Status : Recruiting First Posted : October 4, 2018 Last Update Posted : January 3, 2019 See Sponsor

2018 Clinical Trials

36. Immune privilege disruption in folliculotropic mycosis fungoides: investigation of major histocompatibility complex antigen expression. (PubMed)

Immune privilege disruption in folliculotropic mycosis fungoides: investigation of major histocompatibility complex antigen expression. Folliculotropic mycosis fungoides (FMF) is a cutaneous T-cell lymphoma mainly affecting the hair follicle, which seems to represent a place of immune privilege phenomenon.To explore a possible role of immune privilege (IP) in FMF analyzing the major histocompatibility complex (MHC) expression.Immunohistochemistry for HLA-G and MHC-II was performed to formalin (...) -fixed paraffin-embedded cutaneous skin biopsies of FMF patients (n = 43), conventional mycosis fungoides (CMF; n = 13), alopecia areata (AA; n = 13), and normal scalp skin (NS; n = 12).HLA-G expression was lower in FMF (34%: 14/41) and CMF (18%: 2/11) groups compared to alopecia areata (92%:11/12) and normal scalp skin group (100%: 12/12). MHC-II expression in hair follicle was greater in the FMF group (18/42: 43%) compared to AA (0%) and NS (0%). HLA-G and MHC-II expression in cellular infiltrate

2018 International Journal of Dermatology

37. CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases. (PubMed)

CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases. Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma. Early-stage MF patches or plaques often resemble inflammatory skin disorders (ISDs), including psoriasis and atopic dermatitis. Cell adhesion molecule 1 gene (CADM1), which was initially identified as a tumor suppressor gene in human non-small cell lung cancer, has been reported as a diagnostic marker for adult T-cell leukemia

2018 Journal of American Academy of Dermatology

38. The Potential of Narrow Band UVB to Induce Sustained Durable Complete Remission off-Therapy in Stage I Mycosis Fungoides. (PubMed)

The Potential of Narrow Band UVB to Induce Sustained Durable Complete Remission off-Therapy in Stage I Mycosis Fungoides. Narrow Band UVB (NB UVB) is a first line therapy for stage I Mycosis Fungoides (MF) with complete response (CR) in 75%-85% of patients. However, long-term, off-therapy disease free survival (DFS) data are scarce.To assess the long-term DFS following NB UVB treatment stage I MF.An historic cohort of all stage I MF patients achieving CR with NB UVB and discontinuing any

2018 Journal of American Academy of Dermatology

39. Acneiform follicular mucinosis: an indolent follicular mucinosis variant unrelated to mycosis fungoides? (PubMed)

Acneiform follicular mucinosis: an indolent follicular mucinosis variant unrelated to mycosis fungoides? Follicular mucinosis (FM) can present as an acneiform eruption, and is usually a benign variant of primary FM unrelated to cutaneous T-cell lymphoma (CTCL). We report two cases of women in their twenties who presented with an acneiform rash on the face, arms and back. In both cases, pathological evaluation of the facial papules revealed predominantly mucinous degeneration of the follicular (...) epithelium, with insufficient lymphocytic infiltration or atypia to diagnose mycosis fungoides. These cases are similar to previous reports of acneiform FM. As none of the reported cases progressed to CTCL, we consider that overdiagnosis and overtreatment should be avoided in acneiform FM, but recommend long-term follow-up.© 2018 British Association of Dermatologists.

2018 Clinical & Experimental Dermatology

40. Retinoic Acid Receptor Agonist as Monotherapy for Early-Stage Mycosis Fungoides: Does it Work? (PubMed)

Retinoic Acid Receptor Agonist as Monotherapy for Early-Stage Mycosis Fungoides: Does it Work? Retinoids exert their biologic effects by binding to intracellular retinoic-acid receptors (RARs) and/or retinoid X receptors (RXRs). Early-stage mycosis fungoides (MF) has been effectively treated with bexarotene, an RXR-agonist, with overall response (OR) rates 54-67% and complete response (CR) rates 7-27%. Data on RAR-agonist monotherapy are limited.To analyze the effectiveness of RAR-agonist

2018 Journal of Dermatological Treatment

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>